- Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. The Journal of infectious diseases. 2002 Academic Article GET IT
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-Week results. AIDS. 2001 Academic Article GET IT
Highly active antiretroviral therapy.
Times cited: 8